PCM
HUMA icon

Penserra Capital Management’s Humacyte HUMA Stock Holding History

Penserra Capital Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,712
Closed -$8K – 1073
2022
Q2 		$8K Sell
2,712
-983
-27% -$5.46K ﹤0.01% 1307
2022
Q1 		$26K Buy
3,695
+150
+4% +$873 ﹤0.01% 1187
2021
Q4 		$25K Buy
+3,545
New +$35.1K ﹤0.01% 1201

Other funds holding HUMA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Penserra Capital Management's HUMA Position: Q3 2022 in Review

Penserra Capital Management sold out of Humacyte (HUMA) in Q3 2022, closing a stake of 2,712 shares — an estimated $8K sold.

Penserra Capital Management first reported a position in HUMA in Q4 2021 and held it in 3 quarters. The position peaked at $26K in Q1 2022. 70 funds tracked by Wall St. Rank hold HUMA as of Q3 2022.

  • Penserra Capital Management reported no remaining Humacyte position as of Q3 2022 after selling out during the quarter.
  • Penserra Capital Management sold 2,712 Humacyte shares in Q3 2022, an estimated $8K.
  • Penserra Capital Management first reported a position in Humacyte in Q4 2021 and held it in 3 quarters.
  • Penserra Capital Management's Humacyte position peaked at $26K in Q1 2022.
  • 70 funds tracked by Wall St. Rank held Humacyte as of Q3 2022.

Based on Penserra Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.